Skip to content

Genentech The Beginnings of Biotech

Spend $50 to get a free DVD!

ISBN-10: 022604551X

ISBN-13: 9780226045511

Edition: 2013

Authors: Sally Smith Hughes

List price: $16.00
Blue ribbon 30 day, 100% satisfaction guarantee!
what's this?
Rush Rewards U
Members Receive:
Carrot Coin icon
XP icon
You have reached 400 XP and carrot coins. That is the daily max!

Description:

In the fall of 1980, Genentech, Inc., a little-known California genetic engineering company, became the overnight darling of Wall Street, raising over $38 million in its initial public stock offering. Lacking marketed products or substantial profit, the firm nonetheless saw its share price escalate from $35 to $89 in the first few minutes of trading, at that point the largest gain in stock market history. Coming at a time of economic recession and declining technological competitiveness in the United States, the event provoked banner headlines and ignited a period of speculative frenzy over biotechnology as a revolutionary means for creating new and better kinds of pharmaceuticals, untold…    
Customers also bought

Book details

List price: $16.00
Copyright year: 2013
Publisher: University of Chicago Press
Publication date: 4/8/2013
Binding: Paperback
Pages: 232
Size: 6.25" wide x 9.25" long x 0.50" tall
Weight: 0.682
Language: English

Sally Smith Hughes is a historian of science at the Bancroft Library at the University of California, Berkeley. She is the author of The Virus: A History of the Concept and the creator of an extensive collection of in-depth oral histories on bioscience, biomedicine, and biotechnology.

Prologue
Acknowledgments
Inventing Recombinant DNA Technology
Two Scientists on Converging Paths
The Collaboration
Patenting and Politics
Steps toward Commercialization
Creating Genentech
Bob Swanson
Founding Genentech
Legal and Political Obstacles
A Full Business Plan
Proving the Technology
A Portentous Experiment
Switching Targets
Negotiating Research Agreements
Making Somatostatin
Wider Issues
Human Insulin: Genentech Makes its Mark
Seeking Corporate Contracts
Procuring a Facility and Staff
Genentech's Human Insulin Project
The Eli Lilly Contract
Publicity and Expansion
Human Growth Hormone: Shaping a Commercial Future
Competing for Human Growth Hormone
Moving toward Corporate Integration
Scaling Up Insulin and Growth Hormone
Corporate Expansion
An Emerging Culture
Wall Street Debut
Biomania
Exit Strategies
Interferon: The New Wonder Drag?
Run-Up to an Initial Public Offering
Legal Impediments
The IPO
Epilogue
Notes
Bibliography
Oral History Bibliography
Index